CTOs on the Move

Contract Pharmaceuticals Limited

www.cplltd.com

 
CPL is a leading contract development and manufacturing organization (CDMO) that provides development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.cplltd.com
  • 7600 Danbro Crescent
    Mississauga, ON CAN L5N 6L6
  • Phone: 905.821.7600

Executives

Name Title Contact Details

Similar Companies

Sound Pharmaceuticals

Sound Pharmaceuticals is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STERIS IMS

STERIS Instrument Management Services is a surgical device and instrument management and consulting company.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Daiichi Sankyo

Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.